James L. Gulley

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

Philip W. Kantoff, Thomas Schuetz, Brent A. Blumenstein et al. · Journal of Clinical Oncology · 2010 · 973 citations

Medicine, Immunology, Oncology +17

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

Manish R. Patel, John Ellerton, Jeffrey R. Infante et al. · The Lancet Oncology · 2017 · 588 citations · Full text

Medicine, Oncology, Urology +12

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

Andrea B. Apolo, Jeffrey R. Infante, Ani Sarkis Balmanoukian et al. · Journal of Clinical Oncology · 2017 · 582 citations

Medicine, Oncology, Pharmacology +17

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

Benjamin Boyerinas, Caroline Jochéms, Massimo Fantini et al. · Cancer Immunology Research · 2015 · 456 citations · Full text

Life Sciences, Immunology, Oncology +17

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer

Mary L. Disis, Matthew H. Taylor, Karen Kelly et al. · JAMA Oncology · 2019 · 427 citations · Full text

Medicine, Oncology, Pharmacology +15